NCT00729612View on ClinicalTrials.gov

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

August 14, 2008

Primary Completion Date

December 16, 2011

Study Completion Date

December 16, 2011

Conditions
Lung Cancer
Interventions
DRUG

carboplatin

DRUG

paclitaxel albumin-stabilized nanoparticle formulation

GENETIC

protein expression analysis

OTHER

immunoenzyme technique

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

Trial Locations (1)

43210

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

Celgene Corporation

INDUSTRY

lead

Greg Otterson

OTHER

NCT00729612 - Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter